GlassScriptPhysician profile
Jamshid Lotfi
NPI 1447447545
$869.69
in general payments reported to CMS, 2019-2025
27 companies · $251 in 2025
The $251 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $56.81 · 2021: $189 · 2022: $27.27 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $250.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $120.83 | 2019 | |
| Ucb, INC. | $72.65 | 2019-2025 | Briviact |
| Eisai INC. | $69.08 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $64.98 | 2019-2020 | |
| Sk Life Science, INC. | $57.29 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $51.98 | 2025 | |
| Biogen, INC. | $47.23 | 2019-2022 | |
| Pfizer INC. | $44.00 | 2021 | |
| Neurelis, INC. | $40.44 | 2025 | Valtoco |
| Amneal Pharmaceuticals LLC | $37.19 | 2025 | Crexont |
| Axsome Therapeutics, INC. | $33.95 | 2025 | Symbravo |
| Biohaven Pharmaceuticals, INC. | $29.79 | 2021 | |
| Abbvie INC. | $27.45 | 2025 | |
| Upsher-Smith Laboratories LLC | $25.43 | 2019 | |
| Acorda Therapeutics, INC | $25.22 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $21.36 | 2021 | |
| Genzyme Corporation | $20.56 | 2019 | |
| Lilly USA, LLC | $19.44 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $16.50 | 2025 | Rexulti |
| Lundbeck LLC | $16.43 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.47 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.42 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamshid Lotfi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.